ClinicalTrials.gg
Status unknownNCT02565264Updated Sep 9, 2020

Effect of Plasma Derived Exosomes on Cutaneous Wound Healing

An Early Phase 1 interventional study of plasma-derived exosomes in Ulcer, sponsored by Kumamoto University. Status unknown at 1 site in Japan. Per ClinicalTrials.gov, last updated 2020-09-09.

Sponsored by Kumamoto University · Early Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2019), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Sex
All
01

Study summary

This study is an open prospective clinical trial. The objective is to evaluate the effect of autologous exosomes rich plasma on cutaneous wound healing. The participants are patients with intractable cutaneous ulcers (e.g. rheumatic disease, peripheral arterial disease, chronic venous insufficiency, decubitus or burns). The participants will be treated autologous exosomes rich plasma every day for 28 days. The cutaneous wound healing will be evaluated by the length, width and depth of the wound.

Read the detailed description

Exosomes are small vesicles 0.03-0.1 μm in size, which are shed from most cell types into the extracellular space via intracellular endocytosis. They are found abundantly in body fluids such as blood. They consist of lipid bilayer so that their structure is stable. They can be preserved for 2 weeks at 4℃. They contain proteins, lipids and nucleic acids including coding or non-coding RNA. Resent studies have revealed that exosomes have an important role in cell-to-cell communication.

The investigators found that serum exosome levels were significantly decreased in scleroderma patients with vascular involvements such as cutaneous ulcers and/or pitting scars compared to in normal subjects. The investigators also elucidated that serum-derived exosomes accelerated cutaneous wound healing in BALB/c mice. Exosome supplementation to cutaneous ulcers seems to have significant therapeutic value.

The objective of present study is to evaluate the effect of exosomes derived from plasma on intractable cutaneous ulcers (e.g. rheumatic disease, peripheral arterial disease, chronic venous insufficiency, decubitus or burns).

Autologous exosomes are obtained from the participants' own plasma. The duration of study is 28days. The cutaneous wound healing will be evaluated at day1, day2, day7, day14, day 21 day 28.

02

Conditions studied

  • Ulcer

Browse trials for

03

In context

Ulcer

360 studies on the registry are indexed under Ulcer; 61 are open to participants now.

This study's planned enrollment of 5 is below the median of 65 across 292 interventional studies indexed under Ulcer.

Browse Ulcer studies →

Lead sponsor

Kumamoto University is the lead sponsor of 23 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with intractable cutaneous ulcers (e.g. rheumatic disease, peripheral arterial disease, chronic venous insufficiency, decubitus or burns)

Exclusion criteria

Exclusion Criteria:

  1. Patients who have ulcers with bone involvement.
  2. Patients who have ulcers with a history or suspected neoplasia.
  3. Patients who are in chemotherapy or radiation therapy on the skin ulcers.
  4. Patients with marked immunodeficiency (i.e., patients with severe liver failure, heart failure, hematologic failure or endocrine failure)
  5. Patients who have clinical signs of malnutrition or serum albumin \<2 mg / dL.
  6. Patients who have severe infection.
  7. Patients who are pregnant or breastfeeding.
  8. Patients who are participating in another study.
  9. Patients who are judged inappropriate for this trial by their attending physician.
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    plasma-derived exosomes

    plasma-derived exosomes

    Other: plasma-derived exosomes

Interventions

  • Otherplasma-derived exosomes

    Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.

06

What researchers measure

Primary outcomes

  1. Ulcer size (length, mm)

    Time frame: 28 days

  2. Ulcer size (width, mm)

    Time frame: 28 days

  3. Ulcer size (depth, mm)

    Time frame: 28 days

Secondary outcomes

  1. Pain of cutaneous wounds (Visual Analog Score for pain)

    Time frame: 28 days

07

Study locations

1 site
  • Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University
    Kumamoto, 860-8556, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Sep 2020 and a completion of Sep 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2015
First posted
Oct 1, 2015
Start
Sep 2015
Primary completionEst.
Sep 2020
CompletionEst.
Sep 2020
Last update
Sep 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02565264
Lead sponsor
Kumamoto University
Responsible party
Sponsor
First posted
Oct 1, 2015
Start date
Sep 2015
Primary completion
Sep 2020 (estimated)
Completion
Sep 2020 (estimated)
Last update
Sep 9, 2020

Study contacts

Jinnin Masatoshi, MD, PhD
principal investigator · Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion